These findings are consistent with our bio-informatics-based analyses of gene expression profiles from the TCGA collection of breast cancers indicating that those tumors with the highest Myc levels tend, as a group, to express the lowest levels of miR-206 and the highest levels of MAP3K13 while simultaneously being associated with more adverse clinical outcomes. This evidence concerns the gene MAP3K13 and breast carcinoma.